Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Somewhat Bullish +45

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?

📈 Zimmer Biomet (ZBH) is well-positioned for growth, supported by its People and Culture, Operational Excellence, and Innovation pillars.

📉 The stock has dropped 22% over the past year compared to a 18.3% S&P 500 gain, despite outperforming the industry.

💰 The company holds a market cap of $17.18 billion with an attractive 9.6% earnings yield versus the industry average of 2.6%.

📊 ZBH has surpassed earnings estimates in four consecutive trailing quarters with an average surprise of 2.53%.

👔 Leadership strengthening includes the appointment of Kevin Thornal as group president for Global Businesses and the Americas.

💸 The company generated $1.172 billion in free cash flow in 2025 while navigating tariffs and integrating acquisitions.

🤖 Monogram Technologies was acquired to expand robotics offerings, with commercialization expected alongside Zimmer Biomet implants in early 2027.

🦵 U.S. knee business revenues grew 6% year-over-year in Q4 2025, driven by strong adoption of cementless offerings like Persona OsseoTi.

🎯 Cementless implant penetration reached approximately 35% for the Persona OsseoTi as of late 2025, with a long-term goal to increase further.

🌐 Organic constant currency revenue grew 5.4% in Q4 2025, split between U.S. (5.7%) and international (5%) growth.

⚠️ The company exits 2025 with high leverage, holding $7.52 billion in debt against $591 million in cash, resulting in a 37.2% debt-to-capital ratio.

⚔️ The medical device market remains intensely competitive with rivals including Stryker, Johnson & Johnson, Medtronic, and Smith & Nephew.

📅 Analyst consensus estimates for ZBH project $8.40 EPS and $8.55 billion revenue for 2026, representing a 3.9% revenue increase.

📉 Alternative top-ranked medical stocks include Globus Medical (Zacks #1), Phibro Animal Health (Zacks #1), and Intuitive Surgical (Zacks #2).

Bullish Signals
  • Zimmer Biomet is well-positioned for growth with strong performance in its U.S. knee business, which grew revenues by 6% year-over-year in the fourth quarter of 2025.
  • The company generated $1.172 billion in free cash flow during 2025, reflecting improved cash generation and disciplined capital allocation despite tariff headwinds and acquisitions.
  • Zimmer Biomet surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 2.53%, indicating consistent operational strength.
  • The adoption of cementless offerings continues to accelerate, with the Persona OsseoTi knee reaching approximately 35% penetration of U.S. total knee implants by the end of 2025.
  • Recent acquisition of Monogram Technologies adds surgeon-guided semi and fully autonomous robotic technologies expected to begin commercialization with Zimmer Biomet implants in early 2027.
  • Organic constant currency revenue growth of 5.4% was delivered in Q4 2025, supported by healthy end markets and improved procedure volumes globally.
  • The company completed a strategic focus on innovation and diversification, contributing to portfolio strength through new product waves like ROSA Knee with OptimiZe.
  • As of the fourth quarter of 2025, Zimmer Biomet held $591 million in cash and cash equivalents, providing financial flexibility for future investments.
Risk Factors
  • The stock has dropped 22% in the past year compared to the industry's 20.5% fall and is underperforming significantly against the S&P 500 composite which saw 18.3% growth.
  • The company carries a highly leveraged balance sheet with total debt of $7.52 billion and only $591 million in cash and equivalents as of Q4 2025.
  • The debt-to-capital ratio stands at 37.2%, which is considered moderately high and poses a risk for financial flexibility during periods of market stress.
  • Continuing pricing pressure in the global musculoskeletal market, despite reported stability, could threaten future revenue growth if volumes do not fully compensate.
  • The competitive landscape remains intensely fierce with major players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew, and Medtronic requiring constant new product innovation or acquisitions to maintain market share.
  • Analyst consensus estimates for 2026 have remained stagnant at $8.40 EPS over the past 30 days, suggesting limited growth expectations from Wall Street.
  • Revenue growth projections for 2026 are modest at just a 3.9% increase, reflecting cautious near-term visibility despite recent operational improvements.
Full Analysis
Zimmer Biomet (ZBH) is currently positioned with a Zacks Rank of #3, indicating a "Hold" rating, and has seen its stock decline by 22% over the past year, underperforming the broader S&P 500 which grew 18.3% while significantly outpacing the industry's 20.5% fall. The company maintains a market capitalization of $17.18 billion and boasts an earnings yield of 9.6%, which is substantially higher than the industry average of 2.6%. Historically, Zimmer Biomet has consistently surpassed analyst expectations, achieving an average earnings surprise of 2.53% across its trailing four quarters with each quarter exceeding estimates. Growth strategies are being executed through three core pillars: People and Culture, Operational Excellence, and Innovation and Diversification. Under operational excellence, the company generated $1.172 billion in free cash flow for 2025 while managing tariff headwinds and integrating acquisitions. Strategic initiatives include the acquisition of Monogram Technologies to enhance its robotics portfolio with semi-autonomous technologies expected to begin commercialization in early 2027. Additionally, the Persona OsseoTi Cementless Knee achieved approximately 35% penetration in the U.S. market as of the end of 2025, with U.S. knee business revenues growing 6% year over year in the fourth quarter of 2025. Financial stability remains a key consideration, though it presents specific concerns regarding capital structure. Zimmer Biomet exited the fourth quarter of 2025 with $591 million in cash and cash equivalents against total debt of $7.52 billion, resulting in a debt-to-capital ratio of 37.2%, which some investors view as moderately high. Despite this leverage, the global musculoskeletal market has shown stabilization, supported by healthy end markets and improved procedure volumes. The company delivered organic constant currency revenue growth of 5.4% in the fourth quarter of 2025, with U.S. growth at 5.7% and international growth at 5%. Looking ahead to fiscal year 2026, analyst consensus estimates remain steady at $8.40 per share for earnings per share, suggesting a revenue increase to $8.55 billion, which represents a 3.9% rise from the previous year. While Zimmer Biomet faces an intensely competitive landscape with peers like Stryker, Johnson & Johnson's DePuy, Smith & Nephew, and Medtronic, other medical device stocks are drawing comparisons for their ratings and performance. Notably, Globus Medical carries a Zacks Rank #1 with shares rallying 15.9%, Phibro Animal Health also holds a Rank #1 having surged 156.6% over the year, and Intuitive Surgical maintains a Rank #2 with earnings beats in each of the trailing four quarters, though its yield is lower than Zimmer Biomet's.